-
公开(公告)号：US11607426B2
公开(公告)日：2023-03-21
申请号：US16330858
申请日：2017-09-19
申请人： UNIVERSITY OF SOUTH FLORIDA , THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
IPC分类号： A61K35/28 , C12N7/00 , A61P35/00 , A61K45/06 , C12N5/0775
摘要： The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.
-
公开(公告)号：US20220062382A1
公开(公告)日：2022-03-03
申请号：US17523009
申请日：2021-11-10
IPC分类号： A61K38/19 , A61K47/69 , A61K48/00 , A61K38/17 , A61K35/28 , A61K47/59 , A61K9/00 , A61P25/28
摘要： Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.
-
公开(公告)号：US10813935B2
公开(公告)日：2020-10-27
申请号：US15904176
申请日：2018-02-23
发明人： Subhra Mohapatra , Shyam S. Mohapatra , Mark Howell , Rajesh Nair
IPC分类号： A61K31/517 , A61P35/00 , A61K31/496
摘要： Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.
-
公开(公告)号：US11951152B1
公开(公告)日：2024-04-09
申请号：US17025277
申请日：2020-09-18
发明人： Subhra Mohapatra , Shyam S. Mohapatra , Eleni Markoutsa , Alejandro J. Gonzalez , Heta N. Jadhav
IPC分类号： A61K38/12 , A61K9/127 , A61K9/16 , A61K31/4184 , A61K31/704 , A61K47/08 , A61K47/24 , A61P35/00
CPC分类号： A61K38/12 , A61K9/127 , A61K9/1652 , A61K31/4184 , A61K31/704 , A61K47/08 , A61K47/24 , A61P35/00
摘要： This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.
-
公开(公告)号：US20170219564A1
公开(公告)日：2017-08-03
申请号：US15489823
申请日：2017-04-18
CPC分类号： G01N33/5011 , C12N5/0068 , C12N5/0693 , C12N2533/40 , C12N2533/72 , G01N33/5082 , G01N2500/10
摘要： Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.
-
公开(公告)号：US09618501B2
公开(公告)日：2017-04-11
申请号：US14447779
申请日：2014-07-31
CPC分类号： G01N33/5011 , C12N5/0068 , C12N5/0693 , C12N2533/40 , C12N2533/72 , G01N33/5082 , G01N2500/10
摘要： Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.
-
7.发明申请公开(公告)号：US20140336239A1
公开(公告)日：2014-11-13
申请号：US14361537
申请日：2012-12-03
IPC分类号： C12N15/113 , C12N5/0784 , C12N5/0786
CPC分类号： C12N15/113 , A61K47/6807 , A61K47/6849 , A61K47/6929 , C12N5/0639 , C12N5/0645 , C12N5/0647 , C12N15/111 , C12N2310/141 , C12N2310/17 , C12N2320/30 , C12N2501/65 , C12Q1/6883 , C12Q2600/158 , C12Q2600/178
摘要： Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC.
摘要翻译： 提供了用于调节骨髓来源的抑制细胞（MDSC）的分化的方法和组合物。 特别地，本文描述了可用于调节MDSC的分化的miR-142多核苷酸和miR-223多核苷酸。 可以通过增加MDSC中的miR-142和/或miR-223多核苷酸来实现MDSC群体或MDSC群体内的细胞的增加的分化。
-
公开(公告)号：US20240293430A1
公开(公告)日：2024-09-05
申请号：US18594305
申请日：2024-03-04
IPC分类号： A61K31/585 , A61K39/395 , A61P35/00
CPC分类号： A61K31/585 , A61K39/3955 , A61P35/00
摘要： The present disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of withaferin A and an immune checkpoint blocker. Further, the cancer to be treated may be resistant, have developed resistance, or may be susceptible to resistance to treatment with the immune checkpoint blocker alone or in combination with another therapeutic agent other than withaferin A.
-
公开(公告)号：US11911481B2
公开(公告)日：2024-02-27
申请号：US17057153
申请日：2019-05-21
申请人： UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS , University of South Florida
IPC分类号： A61K9/00 , A61K9/127 , A61K47/36 , C12N15/113 , A61K47/54 , A61K47/69 , A61K39/12 , A61K45/06 , B82Y5/00
CPC分类号： A61K47/544 , A61K39/12 , A61K45/06 , A61K47/6939 , B82Y5/00 , C12N15/1131 , C12N2310/122 , C12N2310/14
摘要： This invention provides for a RSV-targeted nanoparticle PMN (RTPMN), combining HR2D anti-fusion peptide, and plasmid encoded siRNA against RSV-NS1 and/or RSV-P gene as a safe, effective and inexpensive anti-RSV prophylaxis and/or therapy.
-
公开(公告)号：US11884906B1
公开(公告)日：2024-01-30
申请号：US18116550
申请日：2023-03-02
发明人： Subhra Mohapatra , Shyam S. Mohapatra , Tao Wang
CPC分类号： C12M23/16 , B01L3/502715 , C12M23/12 , C12M25/14 , C12M41/26 , C12M41/36 , C12N5/0693 , G01N33/5011 , B01L2300/0627 , B01L2300/0819 , B01L2300/0829 , C12N2503/02 , C12N2513/00
摘要： A 4D-perfused tumoroid-on-a-chip platform used in personalized cancer treatment. The platform includes a plate with a plurality of bottomless wells that resides atop a microfluidic channel layer, which in turn resides atop a surface acoustic wave (SAW) based sensor layer that is capable of measuring potential pH values of fluids disposed within the platform. The microfluidic channel layer includes a plurality of bioreactors, with each bioreactor including an inlet well, a culture well, and an outlet well. The inlet well, culture well, and outlet well form a closed system via fluid conduits spanning from the inlet well to the culture well, as well as from the culture well to the outlet well. Due to the fluid flow from the plate to the chip, and from the inlet well to the outlet well on the chip through the culture well, target cell (tumoroid) growth is promoted within the culture well.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.021 秒)
